Skip to main content

Table 1 Baseline characterisstics of evaluable study participants

From: Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

 

N (frequency %) or mean [SD]

Age (years)

66.75 [5.1]

Sex

 Male

5 (42%)

 Female

7 (58%)

Race

 White

11 (92%)

 Black

1 (8%)

Height (cm)

170.4 [7.8]

Weight (kg)

81.4 [11.8]

Body mass index (kg/m2)

27.9 [4.2]

HbA1c (%)

5.9 [0.9]

Histology

 Pancreatic ductal adenocarcinoma

10 (83%)

 Pancreatic adenosquamous carcinoma

2 (17%)

Extent of disease

 Metastatic

10 (83%)

 Locally advanced

2 (17%)

Pretreatment labs

 Albumin (> 3.5 g/dL)

11 (92%)

 CA19-9 (> 35 U/mL)

10 (83%)

 Sodium (mmol/L)

138.8 [2.7]

 Potassium (mmol/L)

3.9 [0.4]

 Creatinine (mg/dL)

0.6 [0.1]

 Calcium (mg/dL)

9.1 [0.7]

 Glucose (mg/dL)

108.8 [25.1]

  1. Data are presented as N (frequency %) or mean (SD)
  2. SD Standard deviation, HbA1c Hemoglobin A1c